Evaluation of stigmatization and quality of life before and after botulinum toxin treatment in hemifacial spasm
Objective: Hemifacial spasm (HFS) is a chronic disease that is characterized by involuntary tonic and clonic contractions of the muscles innervated by the ipsilateral facial…An exuberant cortical γb influences the unmasking and intensity of dyskinesia in 6-OHDA-treated freely-moving rats
Objective: To clarify the pathogenetic role of Beta band (βb) and Gamma band (γb) in 6-OHDA-treated freely-moving rats, by combining histochemical and electrophysiological investigations. Background:…Impact of chronic LD treatment on metabolism, blood flow and blood-brain barrier permeability in the 6-OHDA rat model
Objective: To determine the effects of chronic LD treatment and induction of dyskinesias on cerebral metabolism, blood flow and blood-brain barrier permeability in 6-OHDA rat…Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study
Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…Twelve-week sensor assessment in Parkinson’s disease: Impact on quality of life
Objective: To evaluate the effects of using wearables over a long time period on Health-Related Quality of Life (HRQoL) in Parkinson's disease (PD) patients. Background:…Synaptic homeostasis in Parkinson’s disease: An high-density EEG study in different stage of the disease
Objective: In order to corroborate these findings, we submitted 29 Parkinson's disease (PD) patients with different stage of disease to an all-night high-density EEG (hd-EEG)…Dyskinesias-reduced-self-awareness and theory of mind in Parkinson’s disease: A novel frame of interpretation
Objective: To analyze the existence of a relationship between Dyskinesias-reduced-self-awareness (DRSA) and abilities related to cognitive and affective Theory of Mind (ToM), which may represent…ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study
Objective: To investigate the efficacy and safety of ADS-5102 (amantadine HCl) extended release capsules 340 mg daily at bedtime for the treatment of levodopa-induced dyskinesia…Validation of an electronic motor diary for patients with Parkinson’s disease
Objective: To determine the reliability and compliance to electronic motor diary in patients with PD. Background: Complexity of motor complications in Parkinson's disease (PD) makes…Characterization of striatal TH-immunoreactive cells in chronic and acute L-DOPA treatment in a mice model of Parkinson´s disease
Objective: To characterize Tyrosine Hydroxylase immunoreactive cells (TH-ir) in a mouse model of hemiparkinsonism and L-DOPA induced dyskinesia. Background: L-DOPA-induced dyskinesias (LID) are a severe…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.